Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

(MedPage Today) — First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Among a total of 557 patients, and…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117347

Author :

Publish date : 2025-09-08 00:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

Malnutrition and Infection Rates Increase Before IBD Surgery

Related Posts

It’s Greek to Me: Why Patient Portals Must Speak Plainly

The science behind how fake tan works on your skin

Hurricane Melissa is being fuelled by exceptional ocean heat

Man Resumes Dialysis After 271 Days Living With a Pig Kidney

Here’s Just How Much Lupus Damages the Heart

ATTR Trial’s Safety Freeze; Heart Failure After Twins; Sotatercept Approval Expands

It’s Greek to Me: Why Patient Portals Must Speak Plainly

The science behind how fake tan works on your skin

Hurricane Melissa is being fuelled by exceptional ocean heat

Man Resumes Dialysis After 271 Days Living With a Pig Kidney

Here’s Just How Much Lupus Damages the Heart

ATTR Trial’s Safety Freeze; Heart Failure After Twins; Sotatercept Approval Expands

How Do Sex, Age, and Menopause Affect Inflammation Markers?

Officials Kept Outbreak a Secret; Mysterious Cancer Rise; Stillbirths Undercounted

Categories

Archives